Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com)
The genetic baldness tests will be introduced to Australia by Advanced Hair Studio (AHS). The company has been offering Hair Restoration in Australia and Worldwide for 35 years. AHS has approximately 75 studios Worldwide and offers various treatments from the patented Strand by Strand procedure through to Advanced Laser Therapy.
“Our clients for Advanced Laser Treatment generally fall into the age category of 18-35 and are made up of male and female from all ethnicities,” says Carl Howell, Managing Director of AHS. “We will be offering the Hair DX test to new clients to assist them in identifying if they carry the genetic variations associated with hair loss before offering them treatment to delay the onset of symptoms.”
HairDX’s easy to use genetic test provides an accurate and understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.
“With this entry into Australia, HairDX continues as a global innovator in molecular dermatology. We’re pleased to bring the latest in genetic science to men and women in the Australia and New Zealand through AHS,” says Andy Goren, President & CEO of HairDX, LLC.
New study links genetic mosaicism to lower Alzheimer’s risk in adults with Down syndrome